Anti-inflammatory compounds and uses thereof

Details Anti-inflammatory compounds and uses thereof Anti-inflammatory compounds and uses thereof

2009-04-09

2010-10-12

Desai, Anand U (Department: 1656)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C514S002600, C514S017400

Reexamination Certificate

active

07812118

ABSTRACT:
The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell.

REFERENCES:
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5804374 (1998-09-01), Baltimore et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5846743 (1998-12-01), Janmey et al.
patent: 5851812 (1998-12-01), Goeddel et al.
patent: 5888762 (1999-03-01), Joliot et al.
patent: 5939302 (1999-08-01), Goeddel et al.
patent: 5972655 (1999-10-01), Marcu
patent: 6015787 (2000-01-01), Potter et al.
patent: 6030834 (2000-02-01), Chu et al.
patent: 6831065 (2004-12-01), May et al.
patent: 6864355 (2005-03-01), May et al.
patent: 7049395 (2006-05-01), May et al.
patent: 7534858 (2009-05-01), May et al.
patent: 7538089 (2009-05-01), May et al.
patent: 2002/0156000 (2002-10-01), May et al.
patent: 2003/0054999 (2003-03-01), May et al.
patent: 2005/0143302 (2005-06-01), May et al.
patent: 2006/0293244 (2006-12-01), May et al.
patent: 2009/0286736 (2009-11-01), May et al.
patent: WO-98/52614 (1998-11-01), None
patent: WO-99/01541 (1999-01-01), None
patent: WO-99/29721 (1999-06-01), None
patent: WO-00/01417 (2000-01-01), None
patent: WO-00/29427 (2000-05-01), None
patent: WO-00/31235 (2000-06-01), None
patent: WO-01/83554 (2001-11-01), None
Bower, B.S. et al. “Glicocladium reseum EGIII-like cellulose (partial sequence).”, Database A—Geneseq—032802, Accession No. AAY06332 (Sep. 6, 1999).
Chu, Z-L. et al., “IKKγ Mediates the Interaction of Cellular IκB Kinase with the Tax Transforming Protein of Human T Cell Leukemia Virus Type 1.”The Journal of Biological Chemistry, vol. 274, No. 22, pp. 15297-15300 (1999).
Delhase, M. et al., “Positive and Negative Regulation of IκB Kinase Activity Through IKKβ Subunit Phosphorylation .”Science, vol. 284, pp. 309-313 (1999).
Derossi, D. et al. “The third helix of the Antennapedia homeodomain translocates through biological membranes.”J. Biol. Chem. vol. 269, No. 14, pp. 10444-10450 (1994).
DiDonato, J.A. et al., “A cytokine-responsive IκB Kinase that activates the transcription factor NF-κB.”Nature, vol. 388, pp. 548-554 (1997).
DiDonato, J.A. et al., “Mapping of the Inducible IκB Phosphorylation Sites That Signal Its Ubiquitination and Degradation.”Molecular and Cellular Biology, vol. 16, No. 4, pp. 1295-1304 (1996).
Ghosh, S. et al., “NF- κB and Rel Proteins: Evolutionarily Conserved Mediators of Immune Responses.”Annu. Rev. Immunol. vol. 16, pp. 225-260 (1998).
Harhaj, E.W. et al., “IKKγ Serves as a Docking Subunit of the IκB Kinase (IKK) and Mediates Interaction of IKK with the Human T-cell Leukemia Virus Tax Protein.”The Journal of Biological Chemistry, vol. 274, No. 33, pp. 22911-2291 4 (1999).
Hatada, E.N. et al. “NF-κB and the innate immune response.”Curr. Opin. Immunol.; vol. 12, No. 1, pp. 52-58 (2000).
Ho, A. et al. “Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo.”Cancer Res. vol. 61, No. 2, pp. 474-477 (2001).
Hu, Y. et al., “Abnormal Morphogenesis but Intact IKK Activation in Mice lacking the IKKα Subunit of IκB Kinase.”Science, vol. 284, pp. 316-320 (1999).
Huang et al. “Remodeling of the Transmembrane Segment in Human Glycophorin by Abberrant RNA Splicing.”The Journal of Biological Chemistry, vol. 269, No. 14, pp. 10804-10812 (1994).
Jin, D-Y. et al., “Role of Adapter Function in Oncoprotein-mediated Activation of NF-κB.”The Journal of Biological Chemistry, vol. 274, No. 25, pp. 17402-17405 (1999).
Jin, D-Y. et al., “Isolation of Full-Length cDNA and Chromosomal Localization of Human NF-κB Modulator NEMO to Xq28.”Journal of Biomedical Science, vol. 6, pp. 115-120 (1999).
Kopp, E. et al., “Inhibiton of NF-κB by Sodium Salicylate and Aspirin.”Science, vol. 265, pp. 956-959 (1994).
Li, Q. et al., “Severe Liver Degeneration in Mice Lacking the IκB Kinase 2 Gene.”Science, vol. 284, pp. 321-325 (1999).
Lindgren, M. et al. “Cell-penetrating peptides.”Trends Pharmacol. Sci. vol. 21, No. 3, pp. 99-103 (2000).
May, M.J. et al. “Rel/NF-κB and IκB proteins: an overview.”Cancer Biology, vol. 8, pp. 63-73 (1997).
May, M.J. et al. “Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex.”Science. vol. 289, No. 5484, pp. 1550-1554 (2000).
May, M.J. et al. “Signal Transduction through NF-κB.”Immunolgy Today, vol. 19, No. 2, pp. 80-88 (1998).
Mercurio, F. et al., “IκB Kinase (IKK)-Associated Protein 1, a Common Component of the Heterogeneous IKK Complex.” Molecular and Cellular Biology, vol. 19, No. 2, pp. 1526-1538 (1999).
Ngor et al., in “The Protein Folding Problem and Tertiary Structure Prediction.” 1994. Merz et al. (ed.), Birkhauser, Boston, MA, p. 433 and 492-495.
Regnier, C.H. et al., “Identification and Characterization of an IκB Kinase.”Cell, vol. 90, pp. 373-383 (1997).
Rothwarf, D.M. et al., “IKK- γ is an essential regulatory subunit of the IκB kinase complex.”Nature, vol. 395, pp. 297-300 (1998).
Rudolph, D. et al., “Severe liver degeneration and lack of NF-κB activation in NEMO/IKKγ-deficient mice.”Genes&Development, vol. 14, pp. 854-862 (2000).
Schwarze, Steven R. et al., “In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse,”Science, vol. 285:1569-1572 (1999).
Siebenlist, U. et al., “Structure, Regulation and Function of NF- κB.”Annu. Rev. Cell. Biol., vol. 10, pp. 405-455 (1994).
Takeda, K. et al., “Limb and Skin Abnormalities in Mice Lacking IKKα.”Science, vol. 284, pp. 313-316 (1999).
Traenckner, E.B-M. et al., “Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli.”The EMBO Journal, vol. 14, No. 12 pp. 2876-2883 (1995).
Yamaoka, S. et al., “Complementation Cloning of NEMO, a Component of the IκB Kinase Complex Essential for NF-κB Activation.”Cell, vol. 93, pp. 1231-1240 (1998).
Ye, J. et al., “Regulation of the NF-κB Activation Pathway by Isolated Domains of FIP3/IKKγ, a Component of the IκB-α Kinase Complex.”The Journal of Biological Chemistry, vol. 275, No. 13, pp. 9882-9889 (2000).
Zandi, E. et al. “The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation.”Cell. vol. 91, No. 2, pp. 243-252 (1997).
Zhang, S.Q. et al.,“Recruitment of the IKK Signalosome to the p55 TNF Receptor: RIP and A20 Bind to NEMO (IKK γ) upon Receptor Stimulation.”Immmunity, vol. 12, pp. 301-311 (2000).
Zhong, H. et al., “The Transcriptional Activity of NF-κB Is Regulated by the IκB-Associated PKAc Subunit through a Cyclic AMP-Independent Mechanism.”Cell, vol. 89, pp. 413-424 (1997).

Affiliated with

Also associated with

Rating

Anti-inflammatory compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-inflammatory compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory compounds and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4223916